Table 4.
Natural products that can overcome drug resistance and regulate multiple pathways.
| Compound name | Dose | Pathways1 | Cell model | Chemodrug | IDS2 | Reference |
|---|---|---|---|---|---|---|
| Single compound | ||||||
| Arsenic trioxide | 0.8 μM | MDR1 and GST-π | SGC7901/ADR | Doxorubicin | 2.1 | [82] |
| Berbamine | 20 μM | MDR1 and survivin | K562/A02 | Doxorubicin | 41.2 | [145] |
| Carnosic acid | 25 μM | MDR1 and Bcl-2 | K562/A02 | Doxorubicin | 12.1 | [146] |
| Curcumin | 25 μM | MRP and Bcl-2 | HL60/ADR | Doxorubicin | 4.2 | [147] |
| Emodin | 10 μM | MRP1, Topo II b, GST-π, and Bcl-2 | HL60/ADR | Doxorubicin | 4.1 | [148] |
| Honokiol | 6.5 μg/mL | MDR1 and NFkB | U937/ADR | Doxorubicin | 2.2 | [149] |
| Methylether-scutellarein | 20 μg/mL | ABC and apoptosis genes | JAR/VP16 | Various | 2.5–5.0 | [150] |
| Quercetin | 10 μg/mL | MDR1 and survivin | A549/DDP | Cisplatin | 3.5 | [151] |
| Quercetin | 40 μM | ABC, Bcl-2, and SLC genes | K562/A | Doxorubicin | 3.7 | [152] |
| Quercetin | 40 μM | MDR1, MRP, GST-π, and H-ras | Bel-FU | 5-Fluorouracil | 2.4 | [153] |
| Schizandrin B | 10 μM | MDR1, pPI3K, and pAKT | U-2 OS/ADR | Various | 2.3–2.9 | [154] |
| Schizandrin A | 50 μM | MDR1 and GSH | Various | Various | 41.2–147.5 | [155] |
| Sodium selenite | 10 μM | MDR and Bcl-2 | K562/ADR | Doxorubicin | 2.3 | [156] |
| Tetrandrine | 1 μg/mL | MDR1, survivin, and caspase-3 | BIU87/ADM | Doxorubicin | 5.3 | [157] |
| Herbal extract | ||||||
| Radix bupleuri | 300 μg/mL | MDR1 and TopoIIα | Bel-7402 | Verapamil | 15.6 | [158] |
| Grape seed polyphenols | 6 μg/mL | MDR1 and Bcl-2 | GBC/SD | Various | 3.4–4.5 | [159] |
| Tea polyphenols | 7.5 μg/mL | MRP and Bcl-2 | HL60/VCR | Various | 2.3–9.1 | [160] |
1Levels of protein or mRNA or both were quantified.
2IDS, increase in drug sensitivity (x-fold).
IDS = IC50 in control group/IC50 in experimental group.